$24.55
▼ -1.1% Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing
Raymond James Initiates Aktis Oncology at Strong Buy With $40 Price Target
Overview
52-week range
$15
$29
68% of range
Avg surprise (last 1)
-22.6%
Avg reaction (last 1)
-1.8%
0% positive
Latest IV / EM
132%
EM ±30.1% · $25 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.38 | $-0.31 | -22.6% | — | -1.8% | earnings |
| Mon Mar 31, 2025 | Mar 2025 | $-18.60 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.44 | — |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Revenue | $3M | — | $1M |
| Cost of revenue | — | — | — |
| Gross profit | — | — | — |
| Operating income | $-23M | — | $-18M |
| Net income | $-18M | — | $-15M |
| EPS (diluted) | $-0.38 | — | $-18.60 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Mar 2025 |
|---|---|---|---|
| Cash & equivalents | $372M | $38M | $58M |
| Inventory | — | — | — |
| Total current assets | $544M | $230M | — |
| Total assets | $577M | $265M | — |
| Long-term debt | — | — | — |
| Total liabilities | $71M | $78M | — |
| Total equity | $506M | $-146M | $-102M |